How antiviral pill molnupiravir shot ahead in the COVID drug hunt
nature.com · 628 words · saved by 1 readers
The Merck pill, which could become the first oral antiviral COVID treatment, forces the SARS-CoV-2 coronavirus to mutate itself to death.
Email Bluesky Facebook LinkedIn Reddit Whatsapp X Access to this article via ICE Institution of Civil Engineers is not available. Change institution Buy or subscribe The pharmaceutical firm Merck announced last week that an antiviral pill it’s developing can cut hospitalizations and deaths among people with COVID-19 by half. The results haven’t yet been peer reviewed. But if the drug candidate, molnupiravir, is authorized by regulators, it would be the first oral antiviral treatment for COVID-19. By contrast, the other currently authorized drugs must be delivered intravenously or injected. Acc
saved by
related reading
- At last, a pill that can prevent COVID after exposure to infected peoplenature.com
- Scientists make breakthrough towards ‘universal’ antiviral drugsgavi.org
- Interceptinterceptfund.com
- COVID-19 drug discovery and treatment options | Nature Reviews Microbiologynature.com
- Cure all diseasesworksinprogress.news
- Progress Deferred: mRNA Vaccine Development Lessons | IFPifp.org
- AI-discovered drugs will be for sale sooner than you thinkvox.com
- Why were Covid vaccine trials so fast?substack.com
- The story of mRNA: From a loose idea to a tool that may help curb Covidstatnews.com
- The sprint to solve coronavirus protein structures — and disarm them with drugsnature.com
- Hard Drugs | Lenacapavir: The miracle drug that could end AIDSharddrugs.worksinprogress.co
- Why are mRNA vaccines so exciting? - Harvard Healthhealth.harvard.edu